Multiple benefits of targeting inflammation in the treatment of type 2 diabetes

One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus

(2015) Edwin J.P. van Asseldonk et al.   CLINICAL IMMUNOLOGY

The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications

(2015) Christian Herder et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Anakinra treatment in patients with gout and type 2 diabetes

(2014) Antonio Vitale et al.   CLINICAL RHEUMATOLOGY

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

(2014) N. A. Di Prospero et al.   DIABETES OBESITY & METABOLISM

Targeting inflammation in the treatment of type 2 diabetes: time to start

(2014) Marc Y. Donath   NATURE REVIEWS DRUG DISCOVERY

The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes

(2013) Allison B. Goldfine   ANNALS OF INTERNAL MEDICINE

Salicylate (Salsalate) in Patients With Type 2 Diabetes

(2013) Allison B. Goldfine   ANNALS OF INTERNAL MEDICINE

A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance

(2013) A. B. Goldfine et al.   DIABETOLOGIA

Psoriasis Severity and the Prevalence of Major Medical Comorbidity

(2013) Howa Yeung et al.   JAMA Dermatology

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Treatment with Anakinra Improves Disposition Index But Not Insulin Sensitivity in Nondiabetic Subjects with the Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

(2011) Edwin J. P. van Asseldonk et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome

(2010) Takara L. Stanley et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

(2009) C. M. Larsen et al.   DIABETES CARE

Inflammation in Atherosclerosis

(2009) Peter Libby et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes

(2008) Allison B. Goldfine et al.   CTS-Clinical and Translational Science

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study

(2008) J. Koska et al.   DIABETOLOGIA

Increased Interleukin (IL)-1β Messenger Ribonucleic Acid Expression in β-Cells of Individuals with Type 2 Diabetes and Regulation of IL-1β in Human Islets by Glucose and Autostimulation

(2008) Marianne Böni-Schnetzler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM